Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.16 USD | -9.41% | -8.61% | +9.03% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Business Summary
Number of employees: 145
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Targeted Protein Degradation
100.0
%
| 31 | 100.0 % | 21 | 100.0 % | -33.25% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 31 | 100.0 % | 21 | 100.0 % | -33.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hirsch
CEO | Chief Executive Officer | 53 | 20-09-13 |
Kendra Adams
DFI | Director of Finance/CFO | 48 | 20-11-19 |
Chief Tech/Sci/R&D Officer | - | 20-12-31 | |
Stewart Fisher
CTO | Chief Tech/Sci/R&D Officer | 57 | 16-04-30 |
Leonard Reyno
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-07-09 |
Courtney Solberg
IRC | Investor Relations Contact | - | - |
Mark Mossler
AUD | Comptroller/Controller/Auditor | 51 | 23-05-31 |
Scott Boyle
PRN | Corporate Officer/Principal | 46 | 21-12-31 |
Adrian Bignami
PRN | Corporate Officer/Principal | - | 21-03-31 |
Jolie Siegel
LAW | General Counsel | 47 | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Downey
CHM | Chairman | 76 | 15-11-30 |
Glenn Dubin
BRD | Director/Board Member | 67 | 21-03-11 |
Bihua Chen
PRN | Corporate Officer/Principal | 55 | 15-11-30 |
Donna Grogan
BRD | Director/Board Member | 67 | 22-07-28 |
Owen Hughes
BRD | Director/Board Member | 49 | Nov. 19 |
Kenneth Anderson
FOU | Founder | 72 | 15-09-30 |
Andrew Hirsch
CEO | Chief Executive Officer | 53 | 20-09-13 |
Malcolm Salter
BRD | Director/Board Member | 84 | 15-11-30 |
Utpal Koppikar
BRD | Director/Board Member | 53 | 22-03-15 |
Laura Bessen
BRD | Director/Board Member | 61 | 22-07-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 68,805,786 | 60,834,824 ( 88.42 %) | 0 | 88.42 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.03% | 424M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- CCCC Stock
- Company C4 Therapeutics, Inc.